A gene therapy approach to treatment of autoimmune disease

Immunologic Research

Volumn 18, Issue 1, 1998, Pages 15-26

  Seroogy, Christine M ^a,b   Fathman, C Garrison ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford California and Cofounder   (United States)

Author keywords

Autoimmunity; Gene therapy; Immune deviation; Th1 CD4+ T cell

Indexed keywords

ANIMAL MODEL; AUTOIMMUNE DISEASE; GENE THERAPY; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031711070     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786510     Document Type: Review

References (49)

1. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases [see comments]. Immunol Today 1995;16, 1:34-38.
2. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway Jr., CA. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177, 1:57-68.
3. van der Veen RC, Stohlman SA. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10. J Neuroimmunol 1993;48, 2:213-220.
4. Kakimoto K, Katsuki M, Hirofuji T, Iwata H, Koga T. Isolation of T cell line capable of protecting mice against collagen-induced arthritis. J Immunol 1988;140, 1:78-83.
5. Swain SL. Generation and in vivo persistence of polarized Th1 and Th2 memory cells. Immunity 1994;1,7:543-552.
6. Bradley LM, Yoshimoto K, Swain SL. The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro. J Immunol 1995;155, 4:1713-1724.
7. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178,6:2123-2130.
8. Creticos PS, Marsh DG, Proud D, Kagey-Sobotka A, Adkinson Jr., NF, Friedhoff L, et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989;84, 2:197-205.
9. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991;88,3 Pt 1:339-348.
10. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25,9:828-838.
11. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92, 2:644-651.
12. Seder RA, Paul WE. Acquisition of lymphokineproducing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-673.
13. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and pro-staglandin E expression in the brain. J Exp Med 1992;176,5:1355-1364.
14. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992; 149,7:2496-2505.
15. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18,7:335-343.
16. Windhagen A, Scholz C, Hollsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995;2,4:373-380.
17. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995; 181,4:1569-1574.
18. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996;379,6563: 343-346.
19. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type II collagen on rheumatoid arthritis [see comments]. Science 1993; 261,5129:1727-1730.
20. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. Science 1997; 276, 5319:1719-1724.
21. Kohn DB. Gene therapy for hematopoietic and immune disorders. Bone Marrow Transplant 1996;18 Suppl 3:S55-S58.
22. Evans CH, Robbins PD, Ghivizzani SC, Hemdon JH., Kang R, Bahnson AB, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996;7, 10:1261-1280.
23. Anderson WF, McGarrity GJ, Moen RC. Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays (February 17, 1993). Hum Gene Ther 1993;4,3:311-321.
24. Qin L, Chavin KD, Ding Y, Tahara H, Favaro JP, Woodward JE, et al. Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol 1996;156,6:2316-2323.
25. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retro-viral vectors through ligand-receptor interactions [see comments]. Science 1994;266,5189: 1373-1376.
26. Crystal RG, Mastrangeli A, Sanders A, Cooke J, King T, Gilbert F, et al. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis. Hum Gene Ther 1995;6,5:667-703.
27. Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus,C, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997;8,1:15-25.
28. Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, Evans CH. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996;39,5:820-828.
29. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997;8,6: 659-669.
30. Qing K, Bachelot T, Mukherjee P, Wang XS, Peng L, Yoder MC, Leboulch P, Srivastava A. Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells. J Virol 1997;71,7:5663-5667.
31. Ponnazhagan S, Erikson D, Kearns WG, Zhou SZ, Nahreini P, Wang XS, Srivastava A. Lack of site-specific integration of the recombinant adeno-associuted virus 2 genomes in human cells. Hum Gene Ther 1997;8,3:275-284.
32. Bongioanni MR, Durelli L, Ferrero B, Imperiale D, Oggero A, Verdun E, et al. Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis. J Neurol Sci 1996; 143,1-2:91-99.
33. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36, 12:1681-1690.
34. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344,8930:1105-1110.
35. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. N Engl J Med 1997;337,3:141-147.
36. Linington C, Engelhardt B, Kapocs G, Lassman H. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 1992;40, 2-3:219-224.
37. Sobel RA, Kuchroo VK. The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein. T cell receptors in inflammatory lesions. J Immunol 1992; 149, 4:1444-1451.
38. McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 1992;38,3:229-240.
39. Shaw MK, Lorens JB, Dhawan A, DalCanto R, Tse HY, Tran AB, et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997;185, 9:1711-1714.
40. Mathisen PM, Yu M, Johnson JM, Drazba JA, Tuohy VK. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997;186,1:159-164.
41. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977;146, 3:857-868.
42. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91,7:2762-2766.
43. Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol 1985;22,3:295-306.
44. Mori L, Iselin S, De Libero G, Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 1996;157, 7:3178-182.
45. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996;26,10:2399-2403.
46. Chernajovsky Y, Adams G, Podhajcer OL, Mueller GM, Robbins PD, Feldmann M. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther 1995;2, 10:731-735.
47. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 1997;4,6:553-559.
48. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and a diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184,3:1093-1099.
49. Moritani M, Yoshimoto K, Li S, Kondo M, Iwahana H, Yamaoka T, et al. Prevention of adoptively transferred diabetes in nonobese diabet with IL-10-transduced islet-specific Th1 lymphocytes. A gene the model for autoimmune diabetes. J Clin Invest 1996;98, 8:1851-1859.